A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (Start I)

AIDS

Volumn 14, Issue 11, 2000, Pages 1591-1600

  Squires, Kathleen E ^a   Gulick, Roy ^b   Tebas, Pablo ^c   Santana, Jorge ^d   Mulanovich, Victor ^e   Clark, Rebecca ^f   Yangco, Bienvenido ^g   Marlowe, Steven I ^h   Wright, David ⁱ   Cohen, Calvin ^j   Cooley, Timothy ^k   Mauney, Joseph ^l   Uffelman, Katharina ^l   Schoellkopf, Nancy ^l   Grosso, Robert ^m   Stevens, Michael ^m  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d San Juan Group   (Puerto Rico)

^e HIV Clinical Research   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^h Advanced Clinical Research   (United States)

ⁱ CTMF HIV Study Group   (United States)

^j Community Research Initiative of New England ^*  (United States)

^k BOSTON MEDICAL CENTER   (United States)

^l PharmaResearch Corporation   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Antiretroviral therapy; Indinavir; Lamivudine; Stawdine; Treatment naive; Zidovudine

Indexed keywords

INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VIREMIA; VOMITING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; THYMIDINE; ZIDOVUDINE;

EID: 0033820968     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00015     Document Type: Article

References (33)

1. Treatment with indinavlr, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced HIV-1 infection and prior antiretroviral therapy
3. Treatment with amprenavir with or without zidovudine plus lamivudine in adults with human immunodeficiency virus infection
4. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 Week follow-up
5. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
6. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
7. Antiretroviral therapy for HIV-1 infection in 1998: Updated recommendations of the International AIDS Society-USA panel
8. A trial comparing nucleoside monotherapy with combination therapy in HIV-1-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
9. Delta: A randomized double-blind trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-1-infected individuals
10. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
11. Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
12. Changes in plasma HIV-1 R.N.A. and CD4+ lymphocyte counts and the risk of progression to AIDS
13. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1-infected adults with 200-500 CD4 cells per cubic millimeter
14. Prognostic value of plasma human deficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/ 116B/117 Team
15. Association of plasma human immunodeficiency virus type 1 RNA level with the risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups
16. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-1 infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
17. Maintenance antiretroviral therapies in HIV-1-infected patients with undetectable plasma HIV-1 RNA after triple-drug therapy
18. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
19. Recovery of replication-competent HIV-1 despite prolonged suppression of plasma viremia
20. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
21. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
22. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
23. Use of changes in plasma levels or human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
24. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy